Company Overview and News

 
Elecon Engineering gains 5% as company reports profit of Rs 7.5cr

2018-08-02 moneycontrol
Shares of Elecon Engineering Company gained 5 percent intraday Thursday as company posted profit in the quarter ended June 2018.
ELECON 505700

 
Tata Global, RInfra, Jindal Saw results

2018-07-31 thehindubusinessline
AB Fashion, Apollo Tyres, Astec Lifesciences, Ballarpur Industries, Exide India, Elecon Engineering, Emami, FDC, Gateway Distriparks, HFCL, HEG, Indoco Remedies, Jayshree Tea, Jindal Saw, Navneet Education, Orient Paper, Pidilite Industries, Poly Medicure, RInfra, Repro India, Tata Global, Thangamayil, Torrent Power, TCI Developers, V2 Retail, Zuari Agro, and Zuari Global are among the 51 firms that will declare their April-June quarter results on Wednesday.
533393 REPRO NAVNETEDUL 531768 532779 TCIDEVELOP 532612 532215 PIDILITIND ZUARIGLOB PDLTY AXISBANK TORNTPOWER 500378 505700 500331 ELECON V2RETAIL AXB KMBKY 500877 INDOCO APOLLOTYRE 532867 ASTEC AYRQY 532622 532687 AXBKY 533138 AXBA ONP 508989 GDL JINDALSAW KOTAKBANK 500102 500247 BALLARPUR 500780 POLYMED

3
Elecon Engineering up nearly 8% after Bajaj Finance acquires additional stake in Co

2018-06-06 moneycontrol
Shares of Elecon Engineering Company gained nearly 8 percent intraday Wednesday as Bajaj Finance acquired additional stake in the company.
ELECON BAJFINANCE 505700 BJJQY 500034

 
BSE, BASF, Subex, CUMI results on Friday

2018-05-03 thehindubusinessline
Over two dozen firms will announce their Q4 and full-year results for the period ended March 2018 on Friday. Among these are Acrow India, Ambuja Cements, Aston Paper, Bhageria Ind, BASF, BSE, Carborundum Universal, Compuage Infocom, Deepak Nitrite, Diamines & Chem, Elecon Engineering, Indo Count, IndBank Merchant, IL&FS Investment, NIIT Tech, Nitta Gelatin, NOCIL, Phillips Carbon, R Systems, SQS India BFSI, Subex, Triton Valves and Voith Paper.
ELECON CARBORUNIV 500425 TRITONV FSIC 533121 513149 AMBUJACEM 513375 COMPUAGE 532456 4977 DEEPAKNI AMBUY 505978 SQSBFSI 505700 ACROW 506401

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to NSE:ELECON / ELECON ENGINEERING CO.LTD. on message board site Silicon Investor.

ACTT: ACT Teleconferencing ACTT: ACT Teleconferencing ACTT: ACT Teleconferencing ACTT - ACT Teleconferencing ACTT - ACT Teleconferencing ACTT - ACT Teleconferencing
VIALOG (VLOG) audio/video teleconferencing VIALOG (VLOG) audio/video teleconferencing VIALOG (VLOG) audio/video teleconferencing Specialty Teleconstructors, Inc. (XMIT) -- EXCITING! Specialty Teleconstructors, Inc. (XMIT) -- EXCITING! Specialty Teleconstructors, Inc. (XMIT) -- EXCITING!